Virax Biolabs shares surge 49.71% intraday after completing UK clinical recruitment and receiving constructive FDA feedback for ViraxImmune™ study.

Virax Biolabs Group surged 49.7% intraday after announcing the completion of UK clinical recruitment for its ViraxImmune™ study and receiving constructive feedback from the FDA regarding its evaluation of T cell dysfunction in post-acute infection syndromes. The news, reported by PR Newswire and highlighted in its CEO’s letter outlining 2026 priorities, signaled regulatory progress and strengthened investor confidence in the company’s pipeline. Recent partnerships with Emory University and Tebubio, along with upcoming FDA meetings, further reinforced optimism about the firm’s long-term prospects in immune diagnostics.